prophylactic dose – Page 2 – Communicable Diseases Research

Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand

Case Report

Published on 2021-09-082022-10-29
Journal: Thrombosis Journal [Category] COVID-19,

A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients

Pharmacology

Published on 2021-09-022022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 95% CI 95% confidence interval Activation all-cause mortality anticoagulation bleeding coronavirus disease COVID-19 COVID-19 patients dose effective Effectiveness Efficacy Endpoint evaluated hazard heparin heparin treatment heparins higher risk Hospital stay hospitalized COVID-19 patients increased risk LMWH LOS low molecular weight major bleeding Meta-analysis Mortality no difference Observational cohort study Patient patients performed potential therapy Prophylactic prophylactic dose Randomized controlled trial Ratio RCT reduced reducing mortality Registration reported review SARS-CoV2 secondary subgroup analysis systematic review therapeutic dose Thromboembolism Treatment unfractionated heparin was performed weight
[DOI] 10.3389/fphar.2021.698008 PMC 바로가기 [Article Type] Pharmacology

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Randomized Controlled Trial

Published on 2021-09-012022-10-05
Journal: Journal of thrombosis and haemostasis : JTH [Category] SARS, 임상,

[키워드] 1:1 95% confidence interval all-cause mortality Anticoagulant anticoagulation arterial assigned bleeding Blood Blood coagulation Chi-square Coagulopathy conducted Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 severity Cox proportional hazard death demonstrated dose enoxaparin Evidence females hazard ratio Hospitalized ICU intensive care intention-to-treat population intermediate dose Laboratory Major major bleeding male Mortality no significant difference not differ occurred Odds ratio Open-label outcome Patient Primary outcome Prophylactic prophylactic dose randomization Randomized controlled trial Randomly receive remains uncertain secondary severe COVID-19 significantly Standard Standard dose therapy thrombosis treated Venous Thromboembolism Venous thrombosis with COVID-19
[DOI] 10.1111/jth.15450 PMC 바로가기 [Article Type] Randomized Controlled Trial

Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19

Observational Study

Published on 2021-08-012022-10-05
Journal: Internal and Emergency Medicine [Category] 임상,

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

COVID-19 관련 응고병증 및 항혈전제 - 1년 후 교훈

Review

Published on 2021-07-012022-09-11
Journal: The Lancet. Haematology [Category] MERS, SARS, 임상, 진단,

[키워드] Anticoagulant Antithrombotic antithrombotic therapy clinical outcomes clinician Coagulation Coagulation system Coagulopathy complex coronavirus COVID-19 Critically ill critically ill patients dose endothelial cells Evidence explained heparin hospital IMPROVE improve clinical outcome incidence insufficiency Local non-critically ill patient non-critically ill patients outcome pathophysiology Patient patients with COVID-19 prophylactic dose Prophylaxis randomised controlled trial Randomised controlled trials recommendations shown Stage systemic inflammatory response the disease therapeutic therapeutic dose These data Thromboprophylaxis thrombosis Thrombosis prophylaxis thrombotic Thrombotic complications Topic Treatment Trial unique with COVID-19
[DOI] 10.1016/S2352-3026(21)00105-8 PMC 바로가기 [Article Type] Review

Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19

Research

Published on 2021-06-112022-10-29
Journal: JAMA Network Open [Category] COVID-19, MERS, SARS,

[키워드] 95% CI adjusted hazard ratio adjusted odds ratio adults hospitalized age analyzed Anticoagulant anticoagulation anticoagulation treatment association Black patients cohort of patient cohort study complication of COVID-19 COVID-19 defined dissemination dose Evidence exposure finding Frequency hospital Hospitalization Hospitalized hospitals implementation Importance In-hospital in-hospital mortality logit lower mortality measure median Missed Mortality mortality rates multicenter objective participant Patient patients hospitalized patients with COVID-19 Point Probability Prophylactic prophylactic dose Prophylaxis ranged Relevance remained Result setting therapy Thromboembolism treated Treatment trend Variation Venous Thromboembolism VTE Weighting with COVID-19 women
[DOI] 10.1001/jamanetworkopen.2021.11788 PMC 바로가기 [Article Type] Research

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

중화 항체 LY-CoV555는 비인간 영장류에서 SARS-CoV-2 감염을 예방합니다

Research Article

Published on 2021-05-122022-09-12
Journal: Science Translational Medicine [Category] MERS, SARS, 비임상, 진단,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus airway airways angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Anti-spike antibody Antigen antigen-specific B cell Antigen-specific B cells B cells bamlanivimab binding characterized clearance clinical testing Clinical use collected conducted convalescent patient coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 demonstrated evaluated functional high-affinity binding Hospitalized in vitro in vivo indications individual infected with SARS-CoV-2 Infection Interaction Jone Jones less Lower respiratory tract LY-CoV555 mAb mAbs monoclonal monoclonal antibodies monoclonal antibody neutralize Neutralizing activity Neutralizing antibodies neutralizing antibody offer patients with COVID-19 pharmacokinetic Population prevented prophylactic dose prophylactic doses prophylactic treatment PROTECT public health threat Receptor-binding domain reduced respiratory distress Respiratory distress syndrome rhesus rhesus macaque SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike severe acute respiratory distress syndrome Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Spectrum Spike protein Support syndrome tested the receptor-binding domain therapeutic therapeutic agent therapeutic option Therapeutics These data Treatment upper and lower respiratory tract upper and lower respiratory tracts vaccination viral replication widespread
[DOI] 10.1126/scitranslmed.abf1906 PMC 바로가기 [Article Type] Research Article

Risk of Clinically Relevant Venous Thromboembolism in Critically Ill Patients With COVID-19: A Systematic Review and Meta-Analysis

Medicine

Published on 2021-03-092022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] 95% CI absence Analysis anticoagulation approach article articles available data bleeding bleeding events calculate clinically conducted Course COVID-19 COVID-19 pandemic Critically ill patient critically ill patients Deep vein thrombosis diagnostic distal DVT English language estimate event Evidence exclusion exploratory Factor high risk Ill incidence inclusion criteria information majority male Meta-analysis meta-regression occurred outcome outcomes Patient patients performed prophylactic dose proximal Pulmonary embolism random-effects model Registered reported Research review Study protocol subsegmental suggested systematic review Thromboembolic event thrombosis Venous Thromboembolism VTE with COVID-19
[DOI] 10.3389/fmed.2021.647917 PMC 바로가기 [Article Type] Medicine

Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

Article

Published on 2021-03-012022-10-30
Journal: Journal of Thrombosis and Thrombolysis [Category] COVID-19, MERS,

[키워드] 95% CI acute respiratory distress adverse event all-cause mortality Anticoagulant appear ARDS association clinical consecutive patient COVID-19 death different dose dosage dose doses Enoxaparin doses evaluated higher risk hospitals In-hospital In-hospital death incidence intubation Italian LMWH low molecular weight mechanical ventilation Mortality multivariable analysis outcome outcome measure overall mortality Patient patients hospitalized patients with COVID-19 primary end-point pro-thrombotic Prophylactic prophylactic dose Randomized regimen secondary significantly lower suggested supplementary material syndrome Thromboprophylaxis thrombotic event treated Treatment Venous Thromboembolism
[DOI] 10.1007/s11239-021-02401-x PMC 바로가기 [Article Type] Article

Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection

COVID-19 감염과 관련된 응고 장애의 위험 관리 및 치료

Review

Published on 2021-01-312022-09-12
Journal: International Journal of Environmental Research an [Category] 진단,

[키워드] abnormality Activation Acute respiratory failure admitted to ICU anticoagulation appear approach Bilateral bilateral pneumonia bleeding Coagulation Coagulopathy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient D-dimer level D-dimer levels Deep vein thrombosis Deep venous thrombosis described Diagnosis disease dose Efficacy and safety Emerging infectious disease Endothelial dysfunction events Evidence feasible feature fibrinogen Frequency individuals with COVID-19 Infectious disease Inpatient institutional protocol intensive care intensive care unit less management Microvascular thrombosis occur overlap Patient Pneumonia Prevent prophylactic dose pulmonary Pulmonary embolism receive Respiratory failure risk severe COVID-19 Symptom systemic inflammation the disease therapeutic therapeutic dose threshold thromboembolic thromboembolic complication thromboembolic complications Thromboembolism Thromboprophylaxis thrombosis thrombotic treat Treatment Venous Thromboembolism Venous thrombosis with COVID-19
[DOI] 10.3390/ijerph18031268 PMC 바로가기 [Article Type] Review